Olaparib is under clinical development by AstraZeneca and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II drugs for Malignant Mesothelioma have a 42% phase ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

The Australian government announces Olaparib now available on the PBS for HER2-negative metastatic breast cancer patients with mutated BRCA1 or BRCA2 gene.

OlympiA is a multicenter, double-blind study in which 1,836 patients with BRCA-positive, HER2-negative breast cancer were randomly assigned (1:1) to receive either olaparib or placebo for one year ...

Australians with prostate and breast cancer now have affordable access to affordable new and expanded medicines under the ...

OlympiA is a multicenter, double-blind study in which 1,836 patients with BRCA-positive, HER2-negative breast cancer were randomly assigned (1:1) to receive either olaparib or placebo for one year ...

SAN ANTONIO — Nearly 10 years along patients with high-risk BRCA-positive breast cancers who had been treated with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza ...

Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...

These data reinforce the importance of germline BRCA testing at the time of diagnosis, so we can identify all eligible patients who may benefit from treatment with olaparib as early as possible." ...

SAN ANTONIO – Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received ...